535
PŘEHLEDOVÉ42522701004388130181216258306358404446
ČLÁNKY88722701003973122176223272
Role4253370100418096131
zánětu57233701003166104140167205
a793337010034
imunity84333701001575112150165192231
u1090337010037
aterosklerózy11433370100346095119158187221238273297336366404
a1563337010034
možné161333701005998129167202
způsoby183133701003169107136176214250
jejich2097337010014496479110147
ovlivnění22613370100377389104141179215253268
30818922701003480121
|325227010043
8.4255530853652
Koenig4925540833573108146161200
W.7085540835767
High-sensitivity790554083445998136159186221259285300322338370386408442
C-reactive1247554083405476110142174198213246280
protein1542554083396198120154169207
and17645540833270109
atherosclerotic1888554083325392127148185212244259294315353375390422
disease:2325554083385379114146173208220
from2561554083184077136
improved271255408314721111331704256540833266105
risk54665408320366292
prediction653654083396195134149181205221259297
to9666540832158
risk-guided103965408321376393113153191206245280320
therapy.1374654083216095116149188219229
Int.161965408314527487
J172265408324
Cardiol1761654083407394132147185201
2013;19786540833468100129141
168:21346540833466101113
5126–5134.2263654083346595128166200231261296309
9.4257530853649
Quispe4907540835291106132171207
R,7127540834054
Michos7827540835975107145183210
ED,1007754083388394
Martin11167540836093114138154192
SS13237540833870
et14087540833962
al.1485754083375265
High-sensitivity15657540835065104142164191226264291306328343376392414448
C-reactive2028754083455981115147179203219251286
protein23297540834465102124158173211
discordance2556754083435884116153175213245283316349
with425854083516689127
atherogenic567854083365896131152189229264302317349
lipid93185408319347389128
measures10748540836297128155192213247274
and13648540833574113
incidence1492854083195789104143178216248281
of17898540834160
atherosclerotic1865854083365796131152189216248263298319357379394426
cardiovascular2306854083366890128143181213246272305342358390411
disease27328540834358841191514259540832661
in5019540831452
primary568954083375974132165186220
prevention:803954083375993125160198219234272311323
the1141954083215994
ARIC1250954083407691132
study.1398954083244885125156166
J158095408323
Am16189540834098
Heart17319540834378110131155
Assoc1902954083396794132165
2020;20829540833367100134147
9:22449540833346
e013600.23059540833369100130165200236249
doi:2569954083377591103
10.1161/2687954083336477108135167197219
JAHA.119.013600.42510540832464109150165195223253264299331361395431467480
10.4251153085367085
Ross52511540833674101127
R.66811540833549
Atherosclerosis73311540834162100135156194220253268303324361388403429
–1177115408335
aninflammatory12271154083327085123141158190248305338360397418452
disease.16941154083395480115147173208220
N1930115408344
Engl199011540833270109124
J2130115408324
Med216911540835590129
1999;23141154083346499135147
340:247711540833469105118
115–126.26111154083346191128159189222235
11.4251253085366577
Horton51712540834179100125161199
JD,7311254083216777
Goldstein8231254083417995133159182215230267
JL,11051254083225367
Brown11861254083335491141179
MS.13801254083528497
SREBPs:14921254083306497132168193206
activators1713125408329608499131163185221242269
of199712540833553
the20651254083195792
complete217112540832965123161177211233266
program24521254083365794133154186243
of271012540833554
cholesterol2779125408328661034251354083155077100133155192208
and64813540833270109
fatty772135408319527498132
acid9191354083326479118
synthesis10521354083265998119158193219234260
in132813540831452
the13951354083226095
liver.1506135408314296296117128
J1649135408324
Clin16891354083405570108
Invest.18121354083155384118145168182
2002;200913540833468104137150
109:217413540833465101114
1125–1131.23031354083346292127163194221251282292
12.4251453085366985
Gurcel52614540835089111142177193
L,73514540833752
Abrami80314540834787109143201217
L,103614540833752
Girardin11041454083496687121143182198237
S1357145408338
et141114540834063
al.14901454083375367
Caspase-1157314540834679107146180207243267299
activation18881454083377095111144178201217255295
of219914540834363
lipid2278145408320367692132
metabolic242614540836399122155195235252267300
pathways27421454083447810114042515540835185117145
in58615540832160
response6621554083276290130170209237273
to95115540832866
bacterial103315540834579112137172194211244260
pore-forming131015540834484107142166187226248308324363403
toxins17301554083276597113152179
promotes192615540834567105165204227262290
cell22321554083387289105
survival.23531554083337193129146179213230243
Cell26131554083468197113
2006;274215540834176113150163
126:4251654083346599112
1134–1145.5531654083356394130168200228260293306
13.4251753085366984
Antonopoulos52417540834786107145184222262302340356394422
AS,9611754083478194
Margaritis107117540836093114153185207223245261288
M,137417540836074
Lee146317540833772108
R1586175408341
et164317540833962
al.17201754083385366
Statins18021754083385992115130168195
as201317540833764
anti-inflammatory20921754083387698114136152191208225258316375408430467489523
agents263117540833777112151172200
in284717540832058
atherogenesis:4251854083325492127149186226261299334361376403415
molekular856185408362101117152182221236269290
rmechanisms116118540832685120153191224262277303361388
and156418540833775115
lessons16941854083205582109147186212
from19221854083234683142
the207918540832765100
recent21951854083266093127165187
clinical23971854083375267105120152186201
trials.2613185408327496597112138152
Curr278118540834581103125
Pharm42519540833573105126184
Des62519540834580107
2012;74819540833468100130142
18:9051954083346578
1519–1530.9981954083346495125163194224257291304
14.4252053085366984
Sahebkar52420540833669107142181212245267
A,80620540834458
Giosia88020540834762100127142174
PD,10692054083388394
Stamerra11792054083355689147182203225258
CA145220540834486
et155420540833759
al.16292054083355063
Effect17072054083365574108141165
of188820540834059
monoclonal196320540836099137175208223262300332348
antibodies23262054083357395110149188227243277304
to264520540832562
PCSK9272320540833879113147182
on42521540833776
high5162154083395493131
sensitivity66221540832863101127142164180212228250284
C-reactive9612154083425577111143175200215247282
protein12582154083406299121155170208
levels:14812154083165183118133159172
a1668215408333
metaanalysis171621540835893115148180218250266298325339366
of209721540833958
16217021540833667
randomised22522154083225593132170229244270305345
controlled261221540833269108129151188204219254293
treatment4252254083224377109131189224262284
arms.72422540833253111138151
Br89122540833556
J963225408324
Clin10022254083405570108
Pharmacol112522540833573105126185217249286302
2016;144222540833569101132144
81(6):16012254083346681115133145
1175–1190.17612254083346291124160191219249285297
15.4252353085366781
Cao52123540833769107
YX,6432354083327285
Li74323540832843
S,80123540833042
Liu8582354083284380
HH,9532354083418598
Li106523540832944
JJ.11242354083214457
Impact119523540831269108140172195
of140523540833453
PCSK9147323540833272106139174
monoclonal166223540835492129167199214251289321336
antibodies20132354083296687102140178217232266292
on232023540833472
circulating2407235408328436494131146178199214251289
hs-CRP27112354083356181123158194
levels:4252454083155082116132158170
a611245408331
systematic6582454083265885109142200233254270302
review9752454083215587103137189
and117924540833270109
meta130324540835792115148
analysis146624540833270102117149176191217
of169824540833857
randomised17702454083215492131169227243269304343
controlled212924540833168106128149186202217252292
trials.2436245408322435991106132146
16.4252553085366985
Tardif5252554083305879117132151
JC,6912554083226376
Kouz78225540833270107137
S,93425540833042
Waters99225540835486107141162189
DD119625540834389
et130025540833154
al.13692554083294457
Efficacy1441255408330486684116148180213
and167025540832967106
safety17912554083235675109132165
of197125540833554
low-dose204025540831351102124164202228263
kolchicine23182554083286581112150165197212250284
after26182554083294872106127
myocardial2760255408355861234252654083316485123139171186
infarction.6262654083155372105126157181197235273286
N928265408344
Engl98826540833270109124
J1128265408324
Med116726540835590129
2019;131226540833468100130143
381:147026540833468100109
2497–2505.15942654083346699132165196231265299311
17.4252753085366876
Nidorf51727540834661100138160181
SM,71427540833388101
Fiolet8312754083334886102137159
ATL,100527540834372104118
Mosterd113827540835694121144178199237
A.139127540834257
Colchicine14632754083417894126164179211226264299
in177727540831654
patients18462754083407395110145183204232
with20942754083516789127
chronic22372754083327091129167182214
coronary24662754083337091129167199220254
disease.273627540833954801151474252854083266173
N514285408344
Engl57428540833270109124
J714285408324
Med75328540835590129
2020;89828540833468101135148
383:106128540833468102114
1838–1847.11902854083346599134171202233269301307
18.3047553085366985
Ridker3148554083355190120154175
PM,33385540833589102
Everett3456554083326398119153175200
BM,36715540833590103
Pradhan3790554083345588127165197235
A404155408340
et40965540833456
al.4167554083324760
Low-dose42425540833169120142182221247282
methotrexate45405540835692114152190212234268299332354387
for4943554083185577
the5035554083215994
prevention5145554083386094126160198220235273312
of54725540833756
atherosclerotic3047654083325492127148185212244259294316353375390422
events.34846540833466101139160188202
N370165408345
Engl37616540833370109125
J390165408324
Med39406540835590130
2019;40856540833468100130143
380:42436540833469104117
752–762.43756540833567101135166198232244
19.3047753085366982
Ridker3144754083375291121156177
PM,33367540833690104
Everett34557540833466100121155177202
BM,36727540833792105
Thuren37927540833473111132166204
T401275408333
et40617540833557
al.4134754083334861
Antiinflamatory42107540834281102117132170188205237295327349386407441
therapy4667754083236196117150189220
with4903754083516790128
canakinumab50467540833265103136166182220258316348387
for5448754083205879
atherosclerotic3047854083325492127148185212244259294316353375390422
disease.3484854083385380115146173208220
N371985408345
Engl37798540833371110125
J392085408324
Med39598540835490129
2017;41038540833569100130140
377:42588540833466101111
1119–1131.4384854083346290120157188216246277286
20.3047953085367389
Abraham31529540834686108142181214272
M,34409540836174
Wald35309540836395111151
H,36969540835064
Vanzel-Ohayon37759540834273112142177193215266306338370408447
D423895408351
et43059540834062
al.4383954083375366
Development44659540835187120155171210250309345384406
of48879540834262
novel49659540834382115150166
promiscuous51469540834567105164179206239277316355382
anti-chemokine30471054083327091107129162200235293332362379417452
peptibodies351410540834076115137152191230270285320346
for38761054083195779
treating39701054083234579111132148185224
autoimmunity42101054083337193130146203261299337352374408
and463310540833472111
inflammation.4759105408316547188120178236268290306344382395
Front51691054083345491130151
Immunol53361054083167413116930471154083387692
Frontiers31541154083325289128149165199221248
2017;341711540833468100130139
8:357211540833446
1432.36331154083356698131143
21.30471253085367082
Hundelshausen314412540834987125164199214240278310348374409447
von360712540833674112
P,373412540834045
Agten379412540834684107140178
SM,398812540833791105
Eckardt41081254083376999132153191214
V4337125408341
et439312540833456
al.44651254083365164
Chemokine454512540834482117175213244260298333
interactome48931254083205879113134167199223260319354
mapping526212540836294133173189226265
enables304713540833472104144159194221
tailored3283135408324577287125147181221
intervention35191354083165476110131166200238259275313351
in388613540831654
acute395513540833466104127160
and413113540833371110
chronic42571354083337192129168183215
inflammation.4487135408317557289121179237269291306344383396
Sci48981354083356782
Transl49951354083355285123149165
Med517513540835692131
2017;532113540833771102132142
9:547813540833649
eaah6650.30471454083346698136172207241275288
22.30471553085367288
O´Neill315015540834665110145160175190
LAJ,335615540833073100112
Kishton34831554083345077114136173211
RJ,37101554083346173
Rathmell37981554083346789127185220235250
J.406415540832335
A4115155408339
guide41701554083377590129164
to434915540832158
immunometabolism442215540831371129167205243301336359391431469485500526584
for50211554083175577
immunologist.511315540831371129167205243259297337352378401414
Nat30471654083457799
Rev316116540833570103
Immunol327916540831573130168206244260
2016;355516540833468100131143
16:37131654083356678
553–565.38071654083346699135169204237249
23.30471753085367287
Mancini314917540835284122154168206221
SJ,33851754083305466
Boyd346617540833371102140
D,362117540834253
Katwan36891754083326687140172210
OJ391417540834467
et399617540833153
al.40641754083294457
Canagliflozin413617540833770108139178193208225242280308323361
inhibits45121754083124987102141156178205
interleukin-1beta-stimulated47331754083124970104125140175212242258296318348383418440473495522544559617654669701722756795
cytokine30471854083316589126157173211246
and330818540832967106
chemokine342918540832967102159198228245282317
secretion37611854083245992113147169184222260
in403718540831250
vascular41021854083296288120158173205226
endothelial434418540833169108146168206241256271303318
cells4678185408329627893119
by481218540833667
AMP-activated489418540833994130151183215239254287320341375414
protein53241854083365795116150165203
kinase-dependent30471954083304684116143178201241276315351389428463501523
and358519540833270109
–independent37091954083355189128163202238276315350388409
mechanism.413419540835792125163195233248274332345
Sci44951954083326479
Rep459019540833570109
2018;471519540833468100131143
8(1):48731954083345385100111
5276.500019540833467100132145
24.30472053085367085
Chackerian314720540833775107139169202223239270308
B,347020540833345
Remaley353020540833368125157172207238
A.378320540833953
Vaccine38512054083336496126141179213
strategies40802054083234667100121155194209243270
for43652054083165374
lowering445420540831350101135156172209248
LDL471720540832974106
by483820540833667
immunization492020540831269127164202217245279300315353391
against532620540832968100115152178201
proprotein30472154083396097137159196218252267305
invertase33672154083155284118139164197223258
subtilisin/kexin364121540832663102124139155170196211248274306340371387425
type40812154083225595131
9.422721540833445
Curr42882154083397697119
Opin442221540834787103140
Lipidol45782154083314786101140178194
2016;478821540833468100131143
27:49462154083346778
345–350.503921540833469102138171204238251
25.30472253085367287
Piepoli31492254083365085124163179194
MF,33582254083558894
Hoes346722540834482118145
AW,362722540834197106
Agewall374922540834179114165198213228
S3993225408332
et404122540833456
al.41122254083324760
2016418822540833468100131
European43342254083336991128167203235273
Guidelines46222254083448297136171187202239274301
on493922540833775
cardiovascular50302254083316485123138176208241268300338353385406
disease54522254083385330472354083266193120155
prevention32172354083416397129163201223238276315
in354723540831755
clinical36172354083344964102117149182197
practice:38302354083416396128152167199233245
The409123540833574109
Sixth42152354083355081105144
Joint43742354083276580118140
Task45292354083356390120
Force46642354083357294125158
of483823540833959
the49122354083246297
European50252354083357193130169205237275
Society531523540833573106121156178212
of304724540833757
Cardiology31192454083417395133148186202240279311
and344624540833270109
Other357124540834871109144166
Societies375224540833371104119154176191226253
on402024540833877
Cardiovascular41122454083417495133148186218251278310348363395416
Disease45442454083466187122154181216
Prevention47752454083365791123157195217232270309
in509924540831553
Clinical51672454083415671109124156189204
Practice.5387245408336568912230472554083223769103115
Eur31772554083336990
Heart328325540834479111132156
J3455255408324
2016;349425540833469100131144
37:36532554083346676
2315–2381.374525540833469100130166198232267299308
26.30472653085367187
Emerging314926540833694129150188203241280
Risk34452654083385480110
Factors35702654083366597121158180207
Collaboration,37922654083448196112144183222243276298313351390403
Kaptoge421026540833872111133170209244
S,447026540833548
Di453326540834964
Angelantonio461326540834482121156172204242263300339354392
E,502026540833649
Pennells508426540833972110148183199214240
L5339265408335
et538926540833760
al.54642654083355063
C-reactive30472754083405375110141174198213246280
protein,33422754083396198120154169207219
fibrinogen,3577275408317347394110148186226261299311
and390427540833270109
cardiovascular40282754083326586124139177209242268301338354386407
disease44502754083395480115147174209
prediction.46742754083396094134149181205221259297310
N5000275408345
Engl506027540833371110125
J5200275408325
Med524027540835590129
2012;538527540833468100130142
367:304728540833469101112
1310–1320.31742854083346495126164195225258292304